0
0
11/15/22 at 2:03pm
Organization
Hcplive.com
Author
Connor Iapoce
31 words
0
Comments
Anti-brolucizumab ADAs may be a risk factor for intraocular inflammation and retinal occlusive vasculitis in patients treated with brolucizumab.
You are the first to view
https://www.hcplive.com/view/brolucizumab-anti-drug-antibodies-prevalent-ophthalmic-patient
Create an account
or login to join the discussion